GSA Capital Partners LLP lifted its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 10.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,893 shares of the company’s stock after purchasing an additional 2,348 shares during the quarter. GSA Capital Partners LLP’s holdings in Ionis Pharmaceuticals were worth $1,211,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after acquiring an additional 417,364 shares during the period. BlackRock Inc. boosted its holdings in Ionis Pharmaceuticals by 4.0% during the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock valued at $347,135,000 after acquiring an additional 264,179 shares during the period. American Century Companies Inc. raised its position in Ionis Pharmaceuticals by 33.0% during the 3rd quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock valued at $58,027,000 after purchasing an additional 284,266 shares in the last quarter. First Trust Advisors LP raised its position in Ionis Pharmaceuticals by 40.2% during the 3rd quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock valued at $49,805,000 after purchasing an additional 281,733 shares in the last quarter. Finally, Northern Trust Corp raised its position in Ionis Pharmaceuticals by 7.8% during the 2nd quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock valued at $31,631,000 after purchasing an additional 44,750 shares in the last quarter. Hedge funds and other institutional investors own 91.40% of the company’s stock.
In other news, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $50.01, for a total value of $1,100,220.00. Following the sale, the chairman now owns 58,014 shares in the company, valued at $2,901,280.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Stanley T. Crooke sold 11,000 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $52.01, for a total value of $572,110.00. Following the completion of the sale, the chairman now owns 48,014 shares in the company, valued at approximately $2,497,208.14. The disclosure for this sale can be found here. In the last quarter, insiders have sold 102,781 shares of company stock worth $5,733,330. Company insiders own 2.13% of the company’s stock.
Ionis Pharmaceuticals Inc (IONS) traded up $0.05 during trading on Friday, reaching $53.22. The company’s stock had a trading volume of 946,534 shares, compared to its average volume of 788,251. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. The stock has a market cap of $6,635.38, a P/E ratio of 354.82 and a beta of 2.86. Ionis Pharmaceuticals Inc has a twelve month low of $37.26 and a twelve month high of $65.51.
Several research firms have recently commented on IONS. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Sunday, September 17th. Barclays reduced their price target on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a research report on Thursday, September 21st. BMO Capital Markets reissued an “outperform” rating and issued a $69.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Goldman Sachs Group reissued a “sell” rating and issued a $30.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $50.76.
TRADEMARK VIOLATION WARNING: “Ionis Pharmaceuticals Inc (IONS) Shares Bought by GSA Capital Partners LLP” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/gsa-capital-partners-llp-has-1-21-million-stake-in-ionis-pharmaceuticals-inc-ions.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.